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Peroxisome proliferator-activated receptors (PPARs)
are pleiotropic regulators of growth and differenti-
ation of many cell types. We have performed a com-
prehensive analysis of the expression of PPARs,
transcriptional cofactors, and marker genes during
differentiation of normal human keratinocytes using
a combination of reverse transcriptase polymerase
chain reaction, Northern and Western blotting, and
immunohistochemistry. PPARd was the predomin-
ant PPAR subtype in human keratinocytes and
highly expressed in basal cells and suprabasal cells.
Induction of PPARa and PPARg expression was
linked to differentiation, and accordingly, expression
of PPARa and PPARg was in essence con®ned to
suprabasal cells. Differentiation was not accompanied
by signi®cant changes in the expression of the co-
activators CREB-binding protein, p300, steroid
receptor coactivator 1, or the corepressors nuclear
receptor corepressor and silence mediator for reti-
noid and thyroid hormone receptors. We critically
evaluated the effects of selective PPAR ligands and a
synthetic fatty acid analog, tetradecylthioacetic acid.
Tetradecylthioacetic acid activated all human PPAR
subtypes in the ranking order PPARd >> PPARa >
PPARg. All selective PPAR ligands marginally
induced transglutaminase-1 expression with the
PPARd-selective ligand L165041 being the most
potent. The PPARa- and PPARg-selective ligands
Wy14643 and BRL49653 had negligible effect on
involucrin expression, whereas a dose-dependent
induction was observed with L165041. Simultaneous
addition of L165041 and BRL49653 synergistically
induced strong involucrin expression. Additionally,
L165041 potently induced CD36 mRNA expression.
Administration of tetradecylthioacetic acid resulted
in a dramatic decrease in proliferation and a robust
upregulation of the expression of involucrin and
transglutaminase. Our results indicate that tetra-
decylthioacetic acid may affect keratinocyte gene
expression and differentiation via PPAR-dependent
and PPAR-independent pathways, and that the




he epidermis is a strati®ed squamous epithelium in
which the basal layer is composed of progenitor cells
that undergo a highly sequential differentiation
program as they leave the basal membrane and rise
through the suprabasal layers. Each step of differenti-
ation is characterized by the expression of speci®c marker genes
(Fuchs, 1990). The transition from the spinous to the granular layer
is accompanied by upregulation of genes encoding structural
proteins of the corni®ed envelope such as involucrin (Inv) and later
transglutaminase-1 (Tg-1) (Rice and Green, 1979; Thacher and
Rice, 1985). Although the stages of differentiation with their
concomitant changes in marker gene expression are well
characterized, relatively little is known about differentiation-
speci®c transcription factors that determine the expression of
speci®c marker genes during differentiation.
Substantial evidence has accumulated implicating classical
nuclear hormone receptors such as the retinoid and vitamin D
receptors in the regulation of epidermal differentiation and function
(Pillai and Bikle, 1991; Itin et al, 1994; Fisher and Voorhees, 1996).
Studies have shown that the retinoid receptors are important for
epidermal development. Thus, ligands of the retinoic acid receptor
(RAR) and the vitamin D receptor modulate epidermal differen-
tiation and proliferation (Hosomi et al, 1983; Floyd and Jetten,
1989; Pillai and Bikle, 1991), and overexpression of a dominant
negative mutant of RARa in the basal layer of epidermis resulted
in a thin epidermis and scaly skin (Saitou et al, 1995). In addition,
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targeting of the dominant negative RARa to the suprabasal layer
led to impaired formation of lamellar membranes, and the
extracellular stratum corneum membranes appeared thinner and
more loosely packed (Imakado et al, 1995). Recently, members of
the peroxisome proliferator-activated receptor (PPAR) subfamily
and the oxysterol-responsive liver x receptor have been implicated
in the control of epidermal differentiation and barrier formation
(Hanley et al, 1999; Komuves et al, 1998, 2000a, b).
The PPAR family comprises three subtypes PPARa, PPARg,
and PPARd. All three subtypes are expressed in human
keratinocytes (Rivier et al, 1998). The PPARs serve as pleiotropic
regulators of cellular proliferation, differentiation, and homeostasis,
and numerous studies have revealed the importance of PPARa and
PPARg in the control of lipid homeostasis (for reviews, see Kersten
et al, 2000; Willson et al, 2000). In contrast, the biologic
signi®cance of PPARd has remained more elusive. PPARd has
been associated with embryo implantation (Lim et al, 1999),
colonocyte growth (He et al, 1999), and cholesterol metabolism
(Leibowitz et al, 2000), and recently the phenotype of PPARd-
de®cient mice was reported (Peters et al, 2000). Interestingly,
PPARd-de®cient mice exhibit an exacerbated hyperplastic re-
sponse to topical application of 12-O-tetradecanoyl-phorbol-13-
acetate on the skin, suggesting that lack of PPARd in¯uences
control of keratinocyte proliferation and/or differentiation (Peters
et al, 2000).
The epidermis represents a tissue with high rates of fatty acid and
cholesterol metabolism where accumulation and deposition of
cholesterol, fatty acids, and sphingolipids constitute an integral part
of the terminal epidermal differentiation program culminating in
the formation of a competent epidermal barrier (Hanley et al, 1997,
1999). Recent work has emphasized the importance of PPARa in
keratinocyte differentiation and barrier formation. Administration
of known PPARa agonists was found to stimulate rodent
keratinocyte differentiation ex vivo (Hanley et al, 1998) and to
accelerate development of the fetal epidermal permeability barrier
(Hanley et al, 1997, 1999). PPARa activators profoundly in¯u-
enced lipid metabolism in reconstructed epidermis (Rivier et al,
2000), and recently it was demonstrated that topical treatment with
PPAR ligands promoted differentiation and reversed induced
hyperproliferation of murine epidermis (Komuves et al, 2000a, b).
Finally, it should be noted that the farnesoid X receptor ligands
farnesol and juvenile hormone III were shown to stimulate
keratinocyte differentiation in a PPARa-dependent manner
(Hanley et al, 2000a). These ®ndings point to PPARa as an
important regulator of epidermal differentiation and homeostasis.
From the analysis of PPARa-de®cient mice it is well documented
that the effects of PPARa agonists on proliferation and expression
of marker genes requires PPARa (Komuves et al, 2000a). No (Lee
et al, 1995) or only minor (Komuves et al, 2000a) defects in
epidermis development and function have been reported in
PPARa-de®cient mice, however. Of interest, systemic adminis-
tration of the PPARg-selective ligand troglitazone was reported to
ameliorate the clinical symptoms of chronic psoriasis and reverse
the abnormal phenotype of transplanted psoriatic skin (Ellis et al,
2000). Yet, administration of PPARg ligands to keratinocytes ex
vivo has consistently been reported not to in¯uence differentiation
(Hanley et al, 1997, 1998). Taken together, these ®ndings suggest
that a critical evaluation of the role of the PPAR family in
keratinocyte differentiation and function would be warranted.
In this study we have analyzed in detail the expression of the
PPARs during ex vivo differentiation of human keratinocytes, in
isolated basal and suprabasal cells, and in sections of human skin.
Using concentrations of PPAR subtype selective ligands that
exclusively targeted the appropriate PPAR subtype we present
evidence that PPARa- and PPARg-selective ligands have negli-
gible effect on keratinocyte marker gene expression. Interestingly,
the PPARd-selective ligand L165041 induced expression of Inv in
a dose-dependent manner. All three PPAR subtype selective
ligands either alone or in combination only modestly affected
keratinocyte proliferation. In contrast, the thiasubstituted fatty acid
tetradecylthioacetic acid (TTA) strongly induced expression of
keratinocyte differentiation marker genes and exerted a profound
antiproliferative action.
Administration of TTA to rats has been shown to induce marked
changes in the pro®le of liver and plasma lipids (Frùyland et al,
1997; Madsen et al, 1997). In this report we show that TTA is a
potent activator of human PPARd and in addition a weak activator
of human PPARa and PPARg. The potency of TTA as an
antiproliferative agent and inducer of keratinocyte marker gene
expression, however, by far exceeded its ef®cacy and potency as a
pan PPAR ligand and could not be recapitulated by combined
addition of PPAR-selective ligands. We suggest that the previously
observed effects on keratinocyte differentiation and function
associated with the administration of high concentrations of
PPAR ligands in part relate to changes in lipid metabolism and/
or accumulation of secondary lipid mediators rather than direct
activation of PPAR-mediated transactivation. Furthermore, our
results suggest that TTA may hold promise as an interesting
compound for the treatment of various epidermal disorders
characterized by hyperproliferation and aberrant differentiation.
MATERIALS AND METHODS
Cell culture and differentiation Keratinocytes from normal adult
human skin specimens were isolated after plastic surgery. First passage
keratinocytes were grown in keratinocyte serum-free medium
(Keratinocyte-SFM; Gibco BRL/Life Technologies, Gaithersburg, MD)
supplemented with 50 mg per ml bovine pituitary extract, 5 ng per ml
human recombinant epidermal growth factor, and 5 mg per ml
gentamycin and replated in 75 cm2 culture ¯asks (Nunc, Roskilde,
Denmark) or at a density of 3500 cells per well in 96-well microtiter
plates (Nunc) preheated at 37°C. Cells were incubated in a humidi®ed
atmosphere of 5% CO2 at 37°C. When cells reached 30%±40%
con¯uency they were treated with Keratinocyte-SFM containing
selective PPAR ligands (either alone or in combination as indicated),
TTA, or 1.2 mM CaCl2. Wy14643 was obtained from Calbiochem,
BRL49653 was kindly provided by J. Fleckner (Novo Nordisk,
Bagsvñrd, Denmark), L165041 was kindly provided by D.E. Moller
(Merck Research Laboratories, Rahway, NJ), and TTA was prepared as
previously described (Spydevold and Bremer, 1989). Cells not treated
with PPAR ligands or TTA received a similar volume of vehicle [0.1%
dimethylsulfoxide (DMSO)]. Medium was changed every day. To
induce differentiation, keratinocytes at 30%±40% con¯uency (day 0)
were treated with 1.2 mM CaCl2. HaCaT cells were obtained from L.
Aarenstrup (Danish Cancer Society, Denmark). HaCaT cells were
cultured in Dulbecco's modi®ed Eagle's medium (DMEM) (Gibco
BRL/Life Technologies) with 10% fetal bovine serum (FBS) and
antibiotics (62.5 mg per ml penicillin, 100 mg per ml streptomycin
sulfate) in a humidi®ed atmosphere of 5% CO2 at 37°C.
Separation of keratinocytes into basal and suprabasal cells Normal
adult skin specimens obtained from plastic surgery were cleaned from fat
and cut through the epidermal side using a scapula. The skin specimens
were incubated overnight on ice with 25 U per ml dispase II (Roche,
Mannheim, Germany) in Hanks' buffered saline solution. The epidermis
was peeled off using a pincer and the epidermal sheets were incubated in
0.05 mg per ml trypsin (Gibco BRL/Life Technologies) at 37°C until
single cells were released. Trypsin activity was inhibited by the addition
of serum-containing medium. The cells were centrifuged at 1200g and
resuspended in preheated Keratinocyte-SFM. The cell suspension was
added to tissue culture ¯asks coated with rat tail collagen (Macklis et al,
1985). After 1 h nonattached cells were collected as the suprabasal
fraction and attaching basal cells were collected using a rubber
policeman. Cell pellets were frozen at ±70°C until use.
Determination of viability and proliferation Viability/proliferation
was measured using a modi®ed thiazolyl blue (MTT) assay (Mosmann,
1983). Twenty-®ve microliters of 5 mg per ml MTT in phosphate-
buffered saline (PBS) (NaCl 8 g per liter, KCl 0.2 g per liter,
Na2HPO4´2H2O 1.44 g per liter, KH2PO4 0.2 g per liter, pH 7.4) were
added to each well, and plates were placed in an incubator until the
growing crystals penetrated the cell walls, typically after 3±4 h. Plates
were ¯icked to remove medium and freeze thawed twice before
formazan crystals were solubilized in ethanol:acetone (60:40 wt/wt) by
gentle shaking for 30 min at 4°C. The amount of formazan was
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quanti®ed in an enzyme-linked immunosorbent assay (ELISA) reader at
540 nm. Background values at 650 nm were subtracted.
Determination of Tg-1 expression by ELISA Cells were subjected
to two freeze±thaw cycles and Tg-1 was determined by ELISA (Michel
et al, 1991). Each well was blocked with 200 ml 1% bovine serum
albumin in PBS for 1 h at 37°C and then incubated for 1 h at 37°C
with 100 ml Tg-1-speci®c monoclonal antibody B.C1 (Biomedical
Technologies, Stoughton, MA) diluted 1:1000 in PBS containing 1%
bovine serum albumin. Wells were washed three times for 5 min in PBS
containing 0.05% Tween 20 and incubated for 1 h with 100 ml
secondary horseradish peroxidase conjugated goat-antimouse antibody
(DAKO, Glostrup, Denmark) diluted 1:2500 in PBS containing 1%
bovine serum albumin. The wells were washed three times with PBS
containing 0.05% Tween 20, and once with PBS. A hundred microliters
of o-phenylenediamine (OPD) substrate was added, and after 30 min in
the dark, reactions were stopped with 100 ml 2 N sulfuric acid. The
amount of Tg-1 was measured by quantifying the OPD reaction with an
ELISA reader at 490 nm and subtracting background at 650 nm. All
values were normalized to the results of the viability assays to correct for
variation in cell number (Svendsen et al, 1997).
Plasmids The hPPARa cDNA was subcloned from pCR2.1hPPARa
(kindly provided by J. Fleckner, Novo Nordisk, Denmark) by partial
digestion with XbaI and BamHI and inserted into the XbaI/BamHI sites of
the pcDNA3.1(+) mammalian expression vector (Invitrogen, San Diego,
CA), generating pcDNA3.1(+)hPPARa. The hPPARd and hPPARg1
cDNAs were excised from pCR2.1hPPARd and pCR2.1hPPARg1
(kindly provided by J. Fleckner) using XbaI/XhoI and inserted into the
XbaI/XhoI sites of pcDNA3.1(+), generating pcDNA3.1(+)hPPARd and
pcDNA3.1(+)hPPARg1. The pcDNA3.1(+)hPPARg2 plasmid was
constructed by ampli®cation of the hPPARg2 cDNA from pSG5
hPPARg2 (kindly provided by A. Elbrecht, Merck Research Laboratories,
Rahway, NJ) by polymerase chain reaction (PCR) using Asp718/XbaI
tagged primers (upstream primer 5¢-AATTGGTACCACCATGGGTG-
AAACTCTGGGAGATTCTCC-3¢ and downstream primer 5¢-CTA-
GTCTAGACTGCTAGTACAAGTCCTTG-3¢) and insertion into the
Asp718/XbaI sites of pcDNA3.1(+). The PPREx3-tk-luc reporter
contains three copies of the peroxisome proliferator-activated receptor
response element (PPRE) from the acyl-CoA oxidase promoter and was
kindly provided by R.M. Evans. A CMV-b-galactosidase vector was used
for normalization (Clontech, Palo Alto, CA).
Transactivation assays HaCaT cells were seeded in 12-well plates
(Nunc) in DMEM containing 10% FBS. After 18 h medium was
changed to DMEM containing 10% stripped bovine serum and
transfections were performed using the BES-CaCl2 method (Chen and
Okayama, 1987). Each well received 35 ml BES reagent (pH 6.95), 35 ml
0.25 M CaCl2, and 0.75 mg PPREx3-tk-luc reporter construct in
combination with expression vectors for either hPPARa (0.01 mg),
hPPARd (0.05 mg), hPPARg1 (0.05 mg), or hPPARg2 (0.05 mg), and
CMV-b-galactosidase (0.1 mg) for normalization. Empty expression
vector was added to ensure equal promoter load and pBluescript(ks +)
was added to a total of 1.2 mg DNA. Cells were incubated with the
transfection mixture at 35°C in an atmosphere of 3% CO2 for 10 h and
washed twice in PBS. Cells were subsequently incubated for ~16 h in
serum-free DMEM containing ligands as indicated or vehicle (0.1%
DMSO). The luciferase and b-galactosidase activities in cell lysates were
determined by standard techniques. Luciferase activities were normalized
to b-galactosidase activities. Transfections were performed in duplicate,
measured in duplicate, and repeated four to six times.
RNA puri®cation Total RNA was puri®ed according to a modi®ed
procedure of Chomczynski and Sacchi (1987). The integrity of all RNA
samples was con®rmed by electrophoresis in denaturing formaldehyde-
containing gels.
Multiplex reverse transcriptase PCR (RT-PCR) Multiplex RT-
PCR was performed essentially as described previously (Jensen et al,
1996; Hansen et al, 1999). All reactions contained the TATA binding
protein (TBP) primer set as an internal standard together with one
additional primer set. The following primer sets (with number of cycles
and amplicon length in parentheses) were used: hPPARa upstream
primer, 5¢-CACAACCAGCACCATCTGGTC-3¢; hPPARa down-
stream primer, 5¢-CCCTTGCAGCCTTCACACGCGTG-3¢ (28 cycles,
395 bp); hPPARd upstream primer, 5¢-GCTATGACTGGGCCTGC-
AGG-3¢; hPPARd downstream primer, 5¢-CCCTTGCACCCCTCA-
CATGCATG-3¢ (25 cycles, 331 bp); hPPARg1 upstream primer, 5¢-
CCTCGAGGACACCGGAGAG-3¢; hPPARg1 downstream primer,
5¢-CCCTTGCATCCTTCACAAGCATG-3¢ (28 cycles, 444 bp);
hPPARg2 upstream primer, 5¢-GGGTGAAACTCTGGGAGATTCTC-
3¢; hPPARg2 downstream primer, 5¢-CCCTTGCATCCTTCACAA-
GCATG-3¢ (28 cycles, 480 bp); CREB-binding protein (CBP) upstream
primer, 5¢-GACATGACTGTCCTGTTTGCC-3¢; CBP downstream
primer, 5¢-GTTGTTATTCTTCCTGCTGG-3¢ (25 cycles, 343 bp);
p300 upstream primer, 5¢-GCCTAAACTCTCATCTCCGG-3¢; p300
downstream primer, 5¢-TAGTGCCCATCCCCATGTTGG-3¢ (25
cycles, 377 bp); nuclear receptor corepressor (NCoR) upstream primer,
5¢-GGTACACAGATTACTTTCCC-3¢; NCoR downstream primer,
5¢-CCAAAGGTGTGATTACACTGG-3¢ (25 cycles, 316 bp); silencing
mediator for retinoid and thyroid hormone receptors (SMRT) upstream
primer, 5¢-TTCTTCAGCAAGCTGACCGAG-3¢; SMRT downstream
primer, 5¢-AGGTGAGTGTGTGGTCACTC-3¢ (28 cycles, 376 bp);
steroid receptor coactivator 1 (SRC-1) upstream primer, 5¢-CCTCTT-
CTTTTGGAGGCTTTGG-3¢; SRC-1 downstream primer, 5¢-ACT-
TCATAACGCTGGCAAGC-3¢ (28 cycles, 320 bp); epidermal fatty acid
binding protein (E-FABP) upstream primer, 5¢-CCATGGCCACAG-
TTCAGCAGC-3¢; E-FABP downstream primer, 5¢-CCAATGCACCA-
TCTGTAAAGTTGCAG-3¢ (25 cycles, 285 bp); CD36 upstream
primer, 5¢-ATTGGTGCTGTCCTGGCTGTG-3¢; CD36 downstream
primer, 5¢-CACCATTGGGCTGCAGGAAAG-3¢ (28 cycles, 316 bp);
Inv upstream primer, 5¢-CTCCTCAAGACTGTTCCTCC-3¢; Inv
downstream primer, 5¢-GCAGTCATGTGCTTTTCCTCTTGC-3¢ (20
cycles, 143 bp); Tg-1 upstream primer, 5¢-GCGGCAGGAGTATGT-
TCTTA-3¢; Tg-1 downstream primer, 5¢-AGGGATGTGTCTGTG-
TCGTG-3¢ (25 cycles, 444 bp); adipocyte lipid-binding protein (ALBP)
upstream primer, 5¢-GGTACCTGGCTTGTCTCC-3¢; ALBP down-
stream primer, 5¢-CCCATTTCTGCACATGTACC-3¢ (20 cycles,
325 bp); TBP upstream primer, 5¢-CTTCGGAGAGTTCTGGGA-
TTGTACC-3¢; TBP downstream primer, 5¢-AATCAGTGCCGTGGT-
TCGTG-3¢ (176 bp). Ten microliters of each reaction was dried down
and resuspended in formamide dye mix and loaded onto 0.3 mm 0.8 M
urea, 1 3 TBE, 6% polyacrylamide gels. Electrophoresis was for 3 h at
40 W. Gels were dried and exposed overnight to PhosphorImager
storage screens. Screens were scanned in a PhosphorImager (Molecular
Dynamics, Sunnyvale, CA).
Northern blotting Total RNA (5 mg per sample) was separated on
1.2% formaldehyde-agarose gels and transferred to Hybond N
membranes (Amersham Pharmacia Biotech, Uppsala, Sweden) by
capillary blotting. RNA integrity was assessed by methylene blue staining
of the membrane. 32P-dCMP labeled probes were generated using
human PPARa, PPARd, PPARg, Inv, keratin 14, and g-actin gene
fragments using the Prime-It labeling Kit (Stratagene, La Jolla, CA). The
probes were puri®ed using microspin G-25 columns (Pharmacia
Biotech). Hybridization with the 32P-labeled probes was carried out by
standard methods. Blots were exposed overnight to PhosphorImager
storage screens. Screens were scanned in a PhosphorImager (Molecular
Dynamics).
Production of anti-PPARd antibodies A tagged cDNA encoding
mouse PPARd was generated by PCR and inserted into the BamHI and
SalI sites of the bacterial expression vector pQE-11 (Qiagen, Valencia,
CA). The PPARd expression vector and a vector expressing the
Escherichia coli chaperones GroEL and GroES were transformed into E. coli
strain BL21 (Novagen, Madison, WI). The details of expression and
puri®cation of active PPARd will be described elsewhere. In short,
PPARd expression was induced by addition of IPTG, and the His-
tagged PPARd was puri®ed by cobalt-af®nity chromatography. The His-
tagged PPARd was eluted with 150 mM imidazole and dialyzed against
PBS (pH 7.3) overnight at 4°C. The purity was determined by sodium
dodecyl sulfate polyacrylamide gel electrophoresis, and the protein
concentration was measured by using the Bio-Rad Protein Assay kit
(Bio-Rad, Hercules, CA).
For production of polyclonal antibodies, 500 mg puri®ed His-tagged
PPARd were mixed with 250 ml incomplete Freund's adjuvant and
injected subcutaneously into a rabbit. Injections were repeated six times
with intervals of 14 d. Anti-PPARd antibodies were af®nity puri®ed
from the antiserum. In short, immune serum was absorbed against GST
immobilized on glutathione-sepharose beads, and anti-PPARd antibodies
were subsequently af®nity puri®ed by binding to a GST±PPARd±A/B
domain fusion protein immobilized on CNBr-activated sepharose.
Bound antibodies were eluted with 0.1 mM glycine-HCl (pH 2.8) and
immediately neutralized in PBS (pH 7.6). The speci®city of the af®nity-
puri®ed anti-PPARd antibodies was assessed by Western blotting.
Western blotting Preparation of whole cell extracts, blotting,
enhanced chemiluminescence, and stripping of membranes was
performed as described previously (Hansen et al, 1999). Protein
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concentrations were determined using the Bradford method (Bio-Rad)
and con®rmed by Coomassie staining of control gels. Forty micrograms
of protein were separated in standard minigels and equal loading/transfer
was con®rmed by amidoblack staining of membranes. Membranes were
blocked overnight in Tris-buffered saline (TBS) containing 5% nonfat
dry milk and 0.1% Tween 20. Incubation with primary and secondary
antibodies was performed in TBS containing 5% nonfat dry milk for
1.5 h. After incubation with antibodies, membranes were washed in TBS
containing 0.1% Tween 20. Primary antibodies used were: mouse
antihuman Tg-1 (1:500) (Biomedical Technologies), mouse antihuman
Inv (1:1000) (Biogenesis, U.K.), mouse anti-PPARa (kindly provided by
J. L. Su, Glaxo Wellcome, NC; Su et al, 1998) (1:8000), mouse anti-
PPARg (E-8; Santa Cruz Biotechnology, Santa Cruz, CA) (1:1000),
rabbit anti-TBP and rabbit anti-TFIIB (C-18 and SI-1; Santa Cruz
Biotechnology) (1:2000), p44/42 mitogen-activated protein kinase
(MAPK) (1:1000), P-p44/42 MAPK (1:1000), Jun amino-terminal kinase
(JNK) (1:500), P-JNK (1:500), p38 MAPK (1:1000), P-p38 MAPK
(1:1000) (all New England Biolabs, Beverly, MA). Secondary antibodies
were horseradish peroxidase conjugated antimouse or antirabbit IgG
antibodies (DAKO, Glostrup, Denmark), both diluted 1:2000. Protein
extracts from 293 overexpressing PPARg2 or PPARd were used as
positive controls. 293 cells were transiently transfected in 60 mm dishes
by the calcium phosphate coprecipitation technique using 10 mg of
PPARg2 or PPARd per dish. The cells were harvested 24 h after
transfection.
Immunostaining Normal human keratinocytes were grown on glass
cover slips in Keratinocyte-SFM. When cells reached 20% con¯uency
they were treated with Keratinocyte-SFM containing selective PPAR
ligands as indicated, TTA, 1.2 mM CaCl2, or a similar volume of vehicle
(0.1% DMSO). Medium was changed every day. On day 3 cells were
®xed in 4% neutral buffered formalin and incubated in blocking buffer
(0.5% Blocking Reagent, Roche, 0.2% Triton) for 20 min. The
permeabilized cells were incubated at room temperature for 1.5 h with
either Alexa 594 (Molecular Probes, Eugene, OR), conjugated anti-Inv
antibody (SY-5, 10 mg per ml) (kindly provided by F.M. Watt, ICRF,
London, U.K.), or Tg-1-speci®c monoclonal antibody (1:50)
(Biomedical Technologies). Cells incubated with Tg-1 antibody were
subsequently incubated for 1 h with Alexa 488 conjugated goat
antimouse IgG antibody (Molecular Probes) 1:400 in blocking buffer.
Nuclei were visualized by staining with Hoechst 33258 (Hoechst,
Germany). Cells were covered with mowiol (Hoechst) based mounting
medium containing 2.5% DABCO (1,4-diazabicyclo-(2,2,2)-octan;
Fluka, Germany) as an antifade reagent. Cells were photographed with a
Photometrics Series 200 cooled CCD camera mounted on a Leica DM
upright microscope using the application IPLab (Scanalytics, Fairfax,
VA). The same exposure time was used and ®les were normalized to the
same standard to enable comparison.
Immunohistochemistry Tissue was ®xed in 3.7% paraformaldehyde
and embedded in paraf®n, and 4±6 mm thick sections were prepared.
Sections were microwaved for 15 min in TEG for detection of PPARa
and PPARg or in 10 mM citrate acetate (pH 6.0) for detection of
PPARd. Blocking was performed overnight and sections were incubated
with antibodies speci®c for PPARd (1:500), PPARa (1:1000) (Su et al,
1998), or PPARg (1:160) (E8; Santa Cruz Biotechnology) at 4°C
overnight. Slides were subsequently incubated with a biotinylated goat
antirabbit or antimouse antibody, and visualized using a standard
streptavidin biotin (LSAB) horseradish peroxidase technique with AEC
(1-amino-9-ethylcarbazol) as chromogen. The slides were counterstained
in hematoxylin and mounted.
RESULTS
Expression of PPARs and cofactors in human keratino-
cytes Normal adult human epidermal keratinocytes were isolated
from human skin obtained after plastic surgery and grown in
serum-free medium. When the cells reached 30%±40% con¯uency,
differentiation was induced by raising the concentration of CaCl2
to 1.2 mM. Total RNA was isolated as indicated during the
following 5 d, and the expression of the three PPAR subtypes (a,
d, and g), cofactors involved in PPAR-mediated transactivation,
and differentiation markers was determined by a combination of
semiquantitative RT-PCR, Northern blotting, and Western
blotting (Fig 1). Using RT-PCR, PPARa and PPARd were
clearly detected on day 0, whereas PPARg was barely detectable. In
agreement with previous reports (Rivier et al, 1998), expression of
PPARa and PPARg1 increased in concert with the increase in Inv
and Tg-1 expression. Expression of PPARd was hardly affected
during differentiation. If anything, the expression of PPARd was
slightly decreased. The PPARg2 isoform was not detectable, and
this together with the fact that the lipid-binding protein aP2/ALBP
(a marker for fat) was undetectable provided evidence that the
cultured normal human keratinocytes were not contaminated with
fat (Fig 1a).
The RT-PCR analysis indicated that PPARd is by far the most
abundantly expressed PPAR subtype in normal human keratino-
cytes in that additional cycles of PCR were required to obtain
signals from the PPARa and PPARg mRNAs. To substantiate this
notion, Northern blotting was carried out. As seen in Fig 1(b),
PPARd is highly expressed, and in accordance with the results
obtained by the RT-PCR analysis its expression level was not
signi®cantly altered during differentiation of normal human
keratinocytes. In contrast, expression of both PPARa and
PPARg was barely detectable by northern blotting. PPARa
mRNA was clearly detectable in cells transfected with the
PPARa expression vector showing that the lack of PPARa
hybridization signals re¯ected the low abundance of PPARa
mRNA in the analyzed human cells (results not shown). Expression
of the PPARd gene is initiated from several distinct promoters
giving rise to a series of different PPARd mRNAs that vary
signi®cantly with respect to translational ef®ciency (L.K. Larsen,
personal communication). Consequently, we examined PPAR
subtype expression during differentiation of normal human
keratinocytes at the protein level by Western blotting. As shown
in Fig 1(c) and paralleling the results obtained by analysis of PPAR
subtype mRNA levels, the PPARd protein remained rather
constant during differentiation, whereas the levels of PPARa and
PPARg1 protein increased.
Figure 1. Expression of PPAR subtypes and PPAR cofactors
during differentiation of human keratinocytes. Pre-con¯uent
normal human keratinocytes were incubated in Keratinocyte-SFM
containing high calcium (1.2 mM) and harvested on days 0, 1, 2, 3, and
5 for preparation of total RNA and whole cell extracts. Note that,
generally, the intensity of signals in the individual panels can only be
compared horizontally. (a) Multiplex RT-PCR analysis of expression of
PPARa, PPARd, PPARg1, PPARg2, Inv, Tg-1, aP2/ALBP, and TBP.
(b) Northern blot analysis of total RNA (5 mg) hybridized with PPARa,
PPARd, PPARg, Inv, and g-actin speci®c probes. Equal loading,
transfer, and integrity of the RNA were veri®ed by methylene blue
staining of 28S rRNA. (c) Whole cell protein extracts were prepared on
the indicated day. 40 mg of protein were loaded in each lane. Expression
of PPARa, PPARd, PPARg1, PPARg2, Inv, and Tg-1 was analyzed by
Western blotting. Equal loading/transfer was con®rmed by amidoblack
staining of membranes and by incubation with anti-TFIIB antibody. (d)
Multiplex RT-PCR analysis of expression of p300, CBP, SRC-1,
NCoR, and SMRT.
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As it is well established that ligand-dependent transactivation of
PPARs is modulated by interactions with both coactivators and
corepressors (for reviews, see Xu et al, 1999; Glass and Rosenfeld,
2000) we examined the expression of a panel of known PPAR
coactivators (p300, CBP, and SRC-1) and corepressors (SMRT
and NCoR) to determine whether their expression was altered in
response to epidermal differentiation. As shown in Fig 1(d),
expression of these cofactors remained remarkably constant during
the course of keratinocyte differentiation.
To compare the results obtained from differentiation ex vivo with
the in vivo situation, we isolated basal and suprabasal cells directly
from human epidermis. Using RT-PCR (Fig 2a) and northern
blotting (Fig 2b) we showed that PPARd was highly expressed in
both the basal and the suprabasal cell fraction with basal cells
exhibiting the strongest signal. Expression of PPARa and PPARg
mRNA was close to the detection limit in basal cells, but
upregulated in suprabasal cells. As it is known that the separation
procedure only results in a crude separation of basal cells from
suprabasal cells, expression markers speci®c for basal cells (keratin
14) and suprabasal cells (Inv) were used to determine the purity of
each cell population. The almost complete lack of Inv expression in
the basal cell fraction suggests that this fraction only had a limited
contamination by suprabasal cells, whereas the clearly detectable
signal from keratin 14 in the suprabasal fraction indicated
contamination by basal cells. The fact that the PPARd signal was
strongest in the basal cell fraction thus indicates that basal cells
exhibit the highest level of PPARd expression. We next compared
the level of expression of the panel of PPAR cofactors at the RNA
level in basal and suprabasal cells. As shown in Fig 2(c) no
signi®cant differences were observed. In summary, using two
different approaches we showed that PPARd is the predominant
PPAR subtype in keratinocytes with a high level of expression in
basal cells. The expression of PPARa and PPARg is considerably
lower, and the pattern of expression is the reverse of that of
PPARd, i.e., low in basal cells and higher in suprabasal cells. Ex vivo
differentiation of normal human keratinocytes largely recapitulated
these ®ndings. PPARd expression was signi®cant, and at most
declined only marginally during differentiation, whereas expression
of PPARa and PPARg initially was at the detection limit but
increased considerably during the course of differentiation.
Immunohistochemical analysis of PPARs in human
epidermis Using in situ hybridization Matsuura et al (1999)
reported that PPARd mRNA was con®ned to the suprabasal layer
of normal human epidermis. This ®nding contrasts with our
observation that PPARd is abundantly expressed in basal cells, and
consequently we decided to perform an immunohistochemical
analysis of PPAR subtype expression in human epidermis (Fig 3).
Sections of human paraformaldehyde ®xed skin were probed with
antibodies speci®c for the individual PPAR subtypes. In keeping
with the results obtained on fractionated human epidermis, strong
PPARd immunoreactivity was apparent in the basal as well as the
suprabasal layers. Interestingly, PPARd appeared to localize both to
nuclei and cytoplasm in the basal cells. In contrast PPARd
immunoreactivity was con®ned to the nuclei in the suprabasal cells.
No PPARa or PPARg immunoreactivity was detectable in basal
cells. In accordance with the differentiation-induced expression of
PPARg, expression of PPARg was detectable in the suprabasal
layer. As PPARd, PPARg exhibited an exclusively nuclear
localization in the suprabasal layer. Surprisingly, very few cells
stained positive for PPARa. The monoclonal anti-PPARa
antibody used is generally considered as a potent antibody for
immunohistochemistry (Su et al, 1998), and using several different
tissues known to express PPARa (liver, kidney, intestine, and
muscle) we detected strong signals of PPARa immunoreactivity
demonstrating the functionality of the antibody (results not shown).
Taken together, our results indicate that expression of PPARa is
very low in human epidermis.
Analysis of the ef®cacy and potency of PPAR-selective
ligands and TTA in transactivation mediated via human
PPAR subtypes Several recent reports have focused on the
involvement of PPARa in epidermal processes such as barrier
development, proliferation, and differentiation; however, little
Figure 3. Expression of PPAR subtypes in
normal human epidermis. Immunohisto-
chemical analyses of PPARa, PPARd, and
PPARg expression and localization in normal
human epidermis. Paraf®n-embedded sections of
normal human epidermis sections were incubated
with puri®ed polyclonal or monoclonal antibody
for PPARd, PPARa, or PPARg at 4°C
overnight. Slides were subsequently incubated
with a biotinylated goat antirabbit or antimouse
antibody, and visualized using a standard
streptavidin biotin (LSAB) horseradish peroxidase
technique. The slides were counterstained in
hematoxylin.
Figure 2. Expression of PPAR subtypes and PPAR cofactors in
basal and suprabasal layers of human epidermis. Total RNA was
puri®ed from populations of enriched basal and suprabasal normal human
keratinocytes isolated from human skin. Note that, generally, the
intensity of signals in the individual panels can only be compared
horizontally. (a) Multiplex RT-PCR analysis of expression of PPARa,
PPARd, PPARg1, PPARg2, Inv, Tg-1, and TBP. (b) Northern blot
analysis of total RNA (5 mg) hybridized with PPARa, PPARd, PPARg,
Inv, keratin 14 (K14), and g-actin speci®c probes. Equal loading, transfer,
and the integrity of the RNA were veri®ed by methylene blue staining
of 28S rRNA. (c) Multiplex RT-PCR analysis of expression of p300,
CBP, SRC-1, NCoR, and SMRT.
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attention has been given to the other PPAR subtypes (Hanley et al,
1997, 1998, 1999; Rivier et al, 1998, 2000; Matsuura et al, 1999;
Komuves et al, 2000a, b). To extend earlier studies, we therefore
decided critically to investigate the possible involvement of the
different PPARs in epidermal differentiation using subtype-
selective ligands. Ligand selectivity and ef®cacy may exhibit cell-
type speci®city, and furthermore, even though PPARa, PPARd,
and PPARg possess distinct ligand-binding speci®cities, few if any
ligands exhibit strict subtype speci®city (for review, see Willson et
al, 2000). Consequently, we undertook a comprehensive analysis of
ligand-dependent PPAR-mediated transactivation in the
spontaneously transformed human keratinocyte cell line HaCaT.
HaCaT cells exhibit a differentiation pro®le comparable with
normal human keratinocytes (Boukamp et al, 1988; Ryle et al,
1989) and were chosen to avoid donor-to-donor variability and
ensure consistency in transfection analyses. HaCaT cells were
transfected with a PPAR-responsive reporter construct and PPAR
expression vectors, and then treated with Wy14643, L165041, and
BRL49653, which are selective for PPARa, PPARd, and PPARg,
respectively (Kliewer et al, 1994, 1995; Forman et al, 1995;
Lehmann et al, 1995; Berger et al, 1999). In addition, we included
the thiasubstituted fatty acid analog TTA that in a concentration-
dependent manner has been shown to activate all three murine
PPAR subtypes (Helledie et al, 2000).1 Figure 4 illustrates the
selectivity, ef®cacy, and potency of the different ligands. As
described previously, BRL49653 exhibited very high speci®city
towards PPARg; only at a concentration of 5 mM was PPARd-
mediated transactivation slightly enhanced. Similarly, 10 mM
Wy14643 selectively targeted PPARa. The PPARd-selective
ligand L165041 clearly is a very potent PPARd activator, which
at concentrations lower than 50 nM targeted PPARd with high
selectivity. TTA was seen to be a very potent PPARd ligand, and,
in keeping with the previous studies using mouse PPARs, it also
induced PPARa- and PPARg-dependent transactivation. It should
be noted that the ligand-induced PPARg-mediated transactivation
was consistently found to be rather modest in HaCaT cells even
though systematic attempts to optimize the transfection protocol
were carried out. PPARg-dependent transactivation is negatively
regulated by MAPK- or JNK-mediated phosphorylation of one
serine residue in the A/B domain (Hu et al, 1996; Camp and
Tafuri, 1997; Camp et al, 1999). We have noticed that normal
human keratinocyte cells exhibited high basal activity of
extracellular signal-regulated kinase 1 (ERK1) and ERK2 MAPK,
and the same phenomenon was observed in HaCaT cells (Fig 5).
Thus, the blunted ligand-induced transactivation of PPARg may be
related to this high basal MAPK activity, and accordingly addition
of an inhibitor of ERKII activation enhanced ligand-induced
transactivation (results not shown).
The effects of PPAR-selective ligands and TTA on epidermal
marker gene expression and cell morphology To evaluate
how the different PPAR activators affected expression of a known
PPAR-responsive gene and differentiation of keratinocytes, we ®rst
measured the mRNA levels of the fatty acid transporter CD36/FAT
and the two differentiation markers Inv and Tg-1 in normal human
keratinocytes treated with PPAR-selective activators over a period
of 3 d (Fig 6a). The proximal promoter of the CD36/FAT gene has
been shown to harbor a PPAR-responsive element, and treatment
with PPARa or PPARg agonists has been reported to induce
expression of the CD36/FAT gene in a tissue-speci®c manner
(Motojima et al, 1998; Tontonoz et al, 1998; Feng et al, 2000). In
keeping with this, administration of BRL49653 or Wy14643
induced expression of CD36/FAT. Interestingly, the PPARd-
selective ligand L165041 induced a dose-dependent expression of
CD36 suggesting that CD36/FAT is also a PPARd-responsive gene.
This is in accordance with the recent ®nding that PPARd also
targets a PPAR-responsive element of the CD36/FAT promoter
Figure 4. Differential activation of PPARa, PPARd, and PPARg
by selective ligands and TTA. HaCaT cells were transiently
transfected with the PPREx3-tk-luc reporter (0.75 mg) and CMV-b-
galactosidase (0.1 mg) in combination with either hPPARa (0.01 mg),
hPPARd (0.05 mg), hPPARg1 (0.05 mg), or hPPARg2 (0.05 mg). In all
transfections empty expression vector was added to ensure equal
promoter load. Cells were incubated with media containing varying
concentrations of Wy14643, L165041, BRL49653, TTA, or vehicle
(0.1% DMSO) for approximately 16 h prior to harvest. Reporter activity
was normalized to b-galactosidase values. All transfections were
performed independently a minimum of four times in duplicate. In each
experiment the transactivation observed with no addition of ligand was
set equal to one to obtain a robust measure of ligand-induced
transactivation. Ligand-dependent fold induction is presented as the mean
6 SD.
Figure 5. HaCaT cells exhibit high basal levels of activated p44/
p42 (ERK1 and ERK2) MAPK. Whole cell extracts were prepared
from HaCaT, 293, and CV-1 cells. 40 mg of protein were separated in
sodium dodecyl sulfate polyacrylamide gels and analyzed for the
expression of total p44/p42 MAPK, JNK, and p38 MAPK, or the
activated form of the kinases. A whole cell extract from ultraviolet-
irradiated 293 cells was used as a positive control (lane 1). Equal loading/
transfer was con®rmed by amidoblack staining of membranes and by
incubation with anti-TFIIB antibody.
1Madsen L, Guerre-Millo M, Berge E, et al: Tetradecylthioacetic acid
induces expression of PPARa target genes, improves insulin sensitivity and
reduces adiposity in two animal models of insulin resistance (submitted).
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(L. Teboul and P.A. Grimaldi, personal communication). The
PPARa-selective agonist Wy14643 induced CD36/FAT expres-
sion to a level comparable to that observed with BRL49653. Finally,
addition of TTA induced expression of CD36/FAT mRNA to a
level slightly higher than those observed with Wy14643 or
BRL49653. Treatment with CaCl2, a well-established and potent
inducer of keratinocyte differentiation, did not induce expression of
CD36/FAT. A number of FABP have been found to be regulated by
PPARs (for review, see Schoonjans et al, 1996) and it has been
discussed whether the E-FABP is also regulated by the PPARs. Here
we show that the expression level of E-FABP mRNA is unchanged
upon treatment of normal human keratinocytes with speci®c PPAR
activators or TTA (Fig 6a), suggesting that PPARs do not regulate
E-FABP expression. This observation is consistent with the
observations of Rivier et al (2000) showing that E-FABP is not
regulated by PPARa agonists in reconstructed epidermis. The
expression pattern of E-FABP contrasts with that of CD36/FAT.
CD36/FAT expression was upregulated by TTA and PPARa-,
PPARg-, or PPARd-selective ligands, but unaffected by CaCl2
treatment, whereas the opposite pattern was found regarding
E-FABP expression.
As shown in Fig 6(a), treatment with Wy14643 resulted in a
modest induction of Inv mRNA expression. Addition of L165041
led to a dose-dependent induction of Inv mRNA expression,
whereas BRL49653 alone had no signi®cant effect on Inv mRNA
expression. Simultaneous addition of L165041 and Wy14643 did
not increase the level of Inv mRNA expression above that observed
with L165041 alone. Similarly, combined treatment with Wy14643
and BRL49653 did not induce Inv mRNA expression above the
level observed with Wy14643 alone. Interestingly, simultaneous
addition of L165041 and BRL49653 strongly induced Inv mRNA
expression, indicating synergy between PPARd and PPARg.
Western blotting essentially recapitulated the results obtained by
RT-PCR showing a dose-dependent induction of Inv protein by
L165041 and a strong synergy between L165041 and BRL49653
(Fig 6b). Each PPAR-selective ligand induced expression of Tg-1
mRNA expression. Of interest, addition of TTA induced expres-
sion of Inv and Tg-1 mRNA to levels that signi®cantly exceeded
those obtained by treatment with the PPAR-selective ligands. The
potency of TTA as an inducer of Inv and Tg-1 expression was even
more dramatic when expression was analyzed at the protein level
by Western blotting (Fig 6b). It should be noted that TTA induced
Inv and Tg-1 mRNA and protein expression to levels equal to or
higher than those observed upon treatment with CaCl2. Taken
together these results suggest that TTA, apart from possibly
inducing Inv and Tg-1 expression via PPAR-dependent pathways,
exerted a pronounced effect on Inv and Tg-1 expression by
mechanisms unrelated to the function of TTA as a PPAR ligand
and activator.
It has been reported that the morphologic changes accompany-
ing CaCl2-induced ex vivo differentiation of normal human
keratinocytes grown on tissue culture plastic are relatively modest
(Gandarillas and Watt, 1997). Most notably, addition of CaCl2
allows the formation of desmosomes leading to the typical pattern
of cells growing in clusters. As the PPAR-selective ligands to
variable degrees, and particularly TTA, upregulated expression of
keratinocyte differentiation markers, we examined whether treat-
ment with TTA or the different subtype-selective PPAR activators
affected normal human keratinocyte morphology during the early
period of the differentiation process. In parallel, expression of Inv
and Tg-1 was examined by indirect immuno¯uorescence micro-
scopy (Fig 7). As evaluated by phase contrast microscopy, the
morphology of normal human keratinocytes treated for 3 d with
ligands or 1.2 mM CaCl2 exhibited notable differences. CaCl2-
treated cells clearly grew in clusters, whereas none of the cells
treated with PPAR ligands or TTA exhibited cluster-like growth.
It appeared that dishes treated with PPAR ligands or TTA
contained more strongly refractile cells with a rounded-up
appearance. Moreover, even though it is not apparent from the
micrographs, the density of cells in dishes treated with TTA was
much lower than vehicle-treated cells or cells treated with PPAR-
selective ligands, indicating that TTA apart from inducing
keratinocyte-speci®c markers also led to growth arrest or a decrease
in the rate of proliferation. This result parallels the decrease in
cellular proliferation and growth arrest associated with induction of
keratinocyte differentiation by treatment with calcium, 1,25-
dihydroxyvitamin D3, oxysteroles, or various PPARa activators
(Pillai and Bikle, 1991; Itin et al, 1994; Hanley et al, 1998, 1999,
2000a, b). Ex vivo differentiation of keratinocytes has been reported
to be associated with changes in cell size (Teumer et al, 1994).
Interestingly, careful comparison of the morphology of CaCl2- and
TTA-treated cells indicated that the cytoplasmic to nuclear ratio of
the TTA-treated cells tended to be smaller than that of CaCl2-
treated cells. Corroborating the results obtained by Western
blotting, indirect immuno¯uorescence microscopy revealed com-
parable levels of expression of Inv and Tg-1 in the CaCl2- and
Figure 6. Induction of epidermal differentiation-speci®c genes
and CD36 in keratinocytes treated with selective PPAR ligands
and TTA. Normal human keratinocytes were incubated for 3 d in
Keratinocyte-SFM containing low calcium (0.09 mM) in the presence of
vehicle (0.1% DMSO), 10 mM Wy14643, 1 mM BRL49653, 5 mM
TTA, and 0.05 mM/0.5 mM L165041 either alone or in combination.
Normal human keratinocytes incubated in high calcium (1.2 mM) served
as a control for differentiation. (a) Total RNA was harvested and
expression of CD36, Inv, Tg-1, E-FABP, and TBP was analyzed by
multiplex RT-PCR. TBP served as internal standard. (b) Whole cell
extracts were prepared and 30 mg of protein were loaded in each lane.
Expression of the differentiation-speci®c genes Inv and Tg-1 was
analyzed by Western blotting. Equal loading/transfer was con®rmed by
amidoblack staining of membranes and by incubation with anti-TBP
antibody.
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TTA-treated cells. Furthermore, this analysis also showed that the
PPARd-selective ligand L165041 induced Inv expression in a dose-
dependent manner. Thus, even though treatment with CaCl2 and
TTA induced overlapping sets of keratinocyte marker genes, this
observation suggests that TTA and CaCl2 exert differential effects
on keratinocyte differentiation.
The effect of TTA on keratinocyte proliferation and
differentiation To examine in a more quantitative manner the
effect of PPAR-selective ligands and TTA on keratinocyte
proliferation, normal human keratinocytes were treated with
PPAR ligands, TTA, and CaCl2 as indicated in Fig 8, and
proliferation was assessed using a modi®cation of the MTT assay as
described in Materials and Methods. In parallel the expression of Tg-
1 was monitored using an ELISA-based assay (Fig 8). In agreement
with the previously published results showing a growth inhibitory
action of clo®brate (Hanley et al, 1998), administration of Wy14643
led to a dose-dependent decrease in normal human keratinocyte
proliferation. BRL49653 also inhibited proliferation, whereas the
effect of L165041 was less pronounced. Combinations of the
different PPAR-subtype-selective ligands did not result in an
inhibition of cellular proliferation exceeding those obtained with
individual ligands. Noteworthy, TTA exerted a strong and dose-
dependent inhibition of normal human keratinocyte proliferation
that by far exceeded that observed for the PPAR-selective ligands.
The antiproliferative action of CaCl2 was only marginal in these
experiments. Recapitulating the results obtained by RT-PCR and
Western blotting, only TTA and CaCl2 signi®cantly induced Tg-1
expression. Thus, the results obtained using the MTT assay clearly
distinguished TTA from PPAR-selective ligands, and substantiated
the notion that TTA strongly inhibited normal human keratinocyte
proliferation and potently induced expression of keratinocyte
differentiation marker genes.
DISCUSSION
In this study we have examined the expression of the individual
PPAR subtypes and cofactors involved in PPAR-mediated
transactivation in human epidermis and cultured keratinocytes.
Combining analyses at the mRNA and protein levels with
immunohistochemistry, we present conclusive evidence that
PPARd is the predominant PPAR subtype in human epidermis.
PPARd is highly expressed in basal cells, and is also abundantly
expressed in the suprabasal layer. During differentiation of human
keratinocytes ex vivo, the level of PPARd expression remained at a
high level. In contrast, expression of PPARa and PPARg1 was low
in undifferentiated keratinocytes, but increased signi®cantly during
differentiation. It was recently reported that the PPARg2 transcript
could be detected in human keratinocytes using RT-PCR (Ellis et
al, 2000). We have been unable to detect PPARg2 mRNA using
RT-PCR, however. In agreement with the analyses of keratino-
cyte cultures induced to differentiate ex vivo and isolated epidermal
fractions, immunohistochemical analyses of sections of human skin
revealed strong PPARd expression in basal as well as in suprabasal
cells. PPARa and PPARg immunoreactivity could not be detected
in the basal cells, but PPARg was clearly present in the suprabasal
layer. This pattern of expression is in accordance with previous
results assaying PPAR subtype expression at the RNA level by RT-
PCR (Rivier et al, 1998), but contrasts with results obtained by
in situ hybridization showing that PPARd expression was con®ned
to the suprabasal level (Matsuura et al, 1999). Considering our
consistent detection of PPARd mRNA and protein in basal cells,
however, it is conceivable that the lack of in situ PPARd mRNA
signals in basal cells might be ascribed to problems associated with
the in situ hybridization technique.
The lack of signi®cant PPARa immunoreactivity in skin
sections was unexpected as a previous study had reported that
PPARa immunoreactivity was associated with nuclei of suprabasal
cells in reconstructed human epidermis (Rivier et al, 2000). RT-
PCR revealed that PPARa mRNA is expressed in suprabasal cells,
but as shown by northern blotting the level of PPARa mRNA was
extremely low. Similarly, even though Western blotting demon-
strated the presence of PPARa in suprabasal cells, the potency of
the antibody used would allow detection of PPARa at the
picogram level. Taken together our ®ndings indicate that PPARa
Figure 7. Morphology and expression of differentiation-speci®c genes in keratinocytes treated with selective PPAR ligands and TTA.
Normal human keratinocytes were incubated for 3 d in Keratinocyte-SFM containing low calcium (0.09 mM) in the presence of TTA or selective
PPAR ligands either in combination or alone as indicated. Normal human keratinocytes incubated in high calcium (1.2 mM) served as a control for
differentiation. Representative ¯asks were photographed on day 3 (phase contrast). Expression of Inv and Tg-1 was determined by immuno¯uorescence
microscopy using Inv (Alexa 594, red) or Tg-1 (Alexa 488, green) speci®c antibodies. Nuclei were visualized by staining with Hoechst 33258 (blue).
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is expressed to very low levels in human epidermis. Of interest,
PPARd was found to localize both to the cytoplasm and the nuclei
in basal cells. In contrast, both PPARd and PPARg exhibited solely
nuclear localization in the suprabasal layer. It remains to be
established whether the intracellular localization of PPARd in basal
cells is in¯uenced by the availability of ligands in analogy with the
ligand-dependent nuclear translocation observed for PPARs in
other cell types (Chinetti et al, 1998; Bishop-Bailey and Hla, 1999;
Kawahito et al, 2000).
The abundant expression of PPARd in basal cells and the
distribution of PPARd between nuclei and cytoplasm make it
tempting to speculate that PPARd may play a role in the
proliferation of keratinocytes, and in a ligand-dependent manner
serve as a molecular switch involved in the initiation of
keratinocyte differentiation. Along this line, it is intriguing that
an analysis of PPAR subtype expression during rat embryonic
development showed that PPARd expression became strongly
upregulated in the epidermis by day 18.5 (Braissant and Wahli,
1998), a time point that coincides with the acceleration of barrier
formation (Hanley et al, 1997).
PPAR-mediated transactivation depends on and is regulated by a
complex interplay of coactivators and corepressors. We analyzed
the expression of prominent cofactors implicated in the control of
PPAR-dependent transactivation during ex vivo differentiation of
keratinocytes and in cells of the basal and suprabasal layer. No
signi®cant changes in the expression of CBP, p300, SRC-1,
NCoR, and SMRT were observed during ex vivo differentiation,
and accordingly basal and suprabasal cells exhibited identical
pro®les of expression of these cofactors.
Previous studies of the role of PPARs in keratinocyte differen-
tiation and function have employed rather high concentrations of
PPAR ligands. To critically evaluate the effect of PPAR-selective
ligands on keratinocyte differentiation and expression of marker
genes, we performed an extensive characterization of ef®cacy and
potency of selective PPAR ligands in the human keratinocyte cell
line HaCaT. In addition, we investigated the capability of the
thiasubstituted fatty acid analog TTA to activate individual PPAR
subtypes. As expected, BRL49653 at concentrations at or below
1 mM targeted only PPARg. Wy14643 at concentrations at or
below 10 mM exhibited PPARa selectivity, and L165041 at
concentrations below 50 nM was a potent and highly speci®c
activator of PPARd. In transactivation experiments using mouse
PPARs, we found that TTA most ef®caciously activated PPARa
(Helledie et al, 2000).1 In this study using human PPARs we
observed that TTA more ef®caciously and potently activated
PPARd, whereas TTA-dependent activation of PPARa and
PPARg was more modest. Using appropriate concentrations of
ligands that secured subtype speci®city we somewhat unexpectedly
found that PPARa- and PPARg-selective ligands alone had a
negligible effect on Inv gene expression. The PPARd-selective
ligand L165041 induced expression of Inv in a dose-dependent
manner, however, and interestingly, simultaneous addition of
L165041 and the PPARg-selective ligand BRL49653 resulted in a
strong synergistic induction of Inv mRNA and protein. It has been
described that PPARd induces PPARg expression in preadipocytes
(Bastie et al, 1999; Hansen et al, 2001). Whether a similar
mechanism is involved in the synergistic activation of Inv
expression in keratinocytes remains to be established.
Activators of PPARa were reported to accelerate epidermal
differentiation and barrier formation (Hanley et al, 1997, 1998,
1999; Rivier et al, 1998; Matsuura et al, 1999; Komuves et al,
2000a, b), and treatment with PPARg-selective ligands was
reported to normalize psoriasis lesions (Ellis et al, 2000). These
results would seem to directly implicate PPARa and PPARg in the
control of keratinocyte differentiation and function. Indeed, the
effect of topical application of the PPARa agonist clo®brate on
epidermal differentiation and marker gene expression was shown to
be dependent on PPARa expression (Komuves et al, 2000a). The
fact that the epidermis of PPARa-de®cient mice appears grossly
normal with only minor detectable differences in comparison with
wild type mice, however, indicates that PPARa does not play a
decisive role in the control of epidermal proliferation and
differentiation, or that other transcription factors may compensate
for the lack of PPARa expression (Komuves et al, 2000a).
Furthermore, a number of observations would seem to argue
against PPARa and PPARg being critical proximal mediators or
executors controlling keratinocyte differentiation and function.
Addition of PPARg ligands to keratinocytes ex vivo does not
in¯uence differentiation (Hanley et al, 1997, 1998). Synergistic
activation of the functional PPARa/retinoid x receptor (RXR)
heterodimer by simultaneous administration of PPARa and RXR
ligands is a characteristic of PPARa-mediated transactivation
(Kliewer et al, 1992; Mukherjee et al, 1998). Yet, no synergistic
effect of PPARa and RXR ligands on keratinocyte differentiation
per se was observed (Hanley et al, 1997). It is known that PPARa
activators profoundly in¯uenced lipid metabolism in reconstructed
epidermis, and in this context synergy between RXR and PPARa
ligands was observed (Rivier et al, 2000). Taken together these
®ndings indicate that the impact of PPAR activators on differen-
tiation to a large extent may be related to subtle alterations in lipid
metabolism and/or accumulation of lipid mediators, and that these
alterations may rely directly and indirectly on PPAR-mediated
processes. This view is also consistent with the strong effect of TTA
on keratinocyte proliferation and marker gene expression. TTA
profoundly affects lipid metabolism in target tissue (Frùyland et al,
1997; Madsen et al, 1997). TTA is a bona ®de PPAR ligand that
Figure 8. TTA induces the late epidermal
differentiation marker Tg-1 and inhibits
proliferation of keratinocytes. Normal human
keratinocytes were seeded into 96-well plates and
incubated for 3 d in Keratinocyte-SFM containing
low calcium (0.09 mM) in the presence of vehicle
(0,1% DMSO), 5 mM TTA, 10 mM Wy14643,
1 mM BRL49653, and 0.05 mM/0.5 mM L
(L165041) either alone or in combination as
indicated. Normal human keratinocytes incubated
in high calcium (1.2 mM) served as a control for
differentiation. MTT assay was performed as
described in Materials and Methods. Tg-1
expression was determined using ELISA. The
values are normalized to MTT viability values as
described in Materials and Methods. Vehicle is set
to 1, and the relative values are normalized
relative to vehicle. Both assays were performed
three times in triplicate. Results are presented as
mean 6 SD.
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preferentially activates human PPARd, and to a lesser extent also
human PPARa and PPARg. The potency of TTA is lower than
the synthetic PPARd-selective ligand L165041, however, and
combinations of the potent synthetic PPAR-selective ligands did
not exert effects on proliferation and marker gene expression of the
same magnitude as those elicited by TTA. In conclusion, we
suggest that the potency of TTA in regulating keratinocyte
differentiation and function results from the unique metabolic
properties of TTA as a relatively potent pan PPAR agonist, and
additionally, TTA is able to markedly alter lipid metabolism in a
PPAR-independent manner. We further propose that alterations in
lipid metabolism possibly leading to the production of lipid
mediators constitute a major pathway involved in the control of
keratinocyte differentiation and function. Finally, the dual func-
tionality of TTA and the fact that it is well tolerated with no
reported adverse side-effects makes TTA an interesting compound
for the treatment of epidermal disorders characterized by
hyperproliferation and aberrant differentiation.
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